52: Hemoglobinopathies Flashcards

1
Q

Where are the α-like and β-like

globin genes clustered?

A

Chromosomes 11 and 16

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

How many α-globin genes are on Chromosome 16?

A

2 α-globin genes

4 total α-globin genes in a normal individual

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

How many β-globin genes are on Chromosome 11?

A

1 β-globin gene

2 β-globin genes in a normal individual

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

HbA

Adult

A

90-95%

α2β2

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

HbF

Fetal

A

1-2%

α2γ2

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

HbA2

A

3-5%

α2δ2

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Embryonic hemoglobins

A

have zeta and epsilion chains.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Hemoglobinopathies

A

family of genetic disorders caused by production of a structurally abnormal hemoglobin or by synthesis of insufficient amounts of
normal hemoglobin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Hemoglobinopathies Qualitatitive change:

A

Mutation in nucleotide sequence of globin chain

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Thalassemia Quantitative change:

A

Decreased or absent globin chain synthesis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Hemoglobin S

A

point mutation in β-globin at 6th position

Glutamate –> Valine (GAG>GTG; missense)

HbS slower to anode than HbA

Homozygous (HbSS): Sickle Cell

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Sickle Cell

A

Autosomal Recessive

Sickle Cell crisis

occlusion of vessels

anemia, hemolysis, and vaso-occulsive ischemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

HbS Treatment

A

Hydroxyurea:

inhibit histone deacetylation leading to more HbF formation

reduced sickling b/c inhibition of HbS polymerization

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

HbAS

A

sickle cell heterozygous carrier

produce normal and abnormal hemoglobin

can develop sickle crisis in low oxygen saturation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Survival Advantage

A

People who inherited one sickle hemoglobin gene (heterozygotes) to combat malaria

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Hemoglobin C

A

point mutation in β-globin at 6th position

Glutamate –> Lysine

moves slowest to anode

mild hemolysis

low solubility, crystallizes in RBC

17
Q

HbSC

A

two different mutations of β-globin gene

S and C mutation

mild sickling episodes

18
Q

Hemoglobin Electrophoresis

A

HbC (- end)
HbS
HbF
HbA(+end)

19
Q

RFLP

A

mutant genes will have larger fragments

20
Q

Thalassemias

A

rate of synthesis of a globin chain is reduced

imbalance alpha/beta chain ratio

21
Q

a-Thalassemia

A

reduced alpha chain synthesis

22
Q

Cause of a-Thalassemia?

A

a-globin gene deletion can be caused by unequal crossing over during homologous recombination

23
Q

Hemoglobin Bart hydrops fetalis (Hb Bart) Syndrome

A

most severe form of a-Thalassemia

cis x cis parents

aggregation of 4 tetramers: γ4 tetramers

All four α-globin alleles are deleted (inactivated) and no HbF or HbA

neonatal death

24
Q

Hemoglobin H (HbH) Diseases

A

deletion of three of the four α-globin alleles

trans x cis parents

infancy or childhood

mild-to-moderate anemia or hepatospenomegaly

bone changes

compatible with survival into adulthood

aggregation of β4 tetramers

25
Q

α-thalassemia carrier/trait

A

deletion or inactivation of two
α-globin genes (cis or trans)

normal or slightly low hemoglobin levels

26
Q

β-thalassemia

A

Autosomal recessive

Allelic heterogeneity

β+ mutation: reduced gene expression

β0 mutation: complete suppression of gene expression

absent or reduced of synthesis of the β-globin chains

Excessive a-globin result in severe
hemolytic anemia

Bone marrow tried to produce more RBC but leads to bone deformity and fractures

27
Q

β-thalassemia major

A

“Cooley’s Anemia’ and ‘Mediterranean
Anemia”

homozygotes or compound heterozygotes for β0 or β+ genes (two severe mutations)

mutations in both β- globin genes

Very low or absent HbA levels

High HbA2 and HbF levels

28
Q

β-thalassemia intermedia

A

homozygotes or compound heterozygotes

(different β+ mutations
on the β-globin genes)

one severe mutation, second mutation is less
severe or two less severe mutations

Low HbA levels

High HbA2 and HbF levels

29
Q

β-thalassemia minor

A

“β-thalassemia carrier, β-thalassemia trait, or heterozygous β-thalassemia”

one normal, one mutant β-globin gene

Almost normal HbA levels

30
Q

Carrier screening

A

introduced in several Mediterranean populations to reduce number of newborns with thalassemia

31
Q

Molecular basis of β-thalassemia

A

mutations in HBB gene on Chromosome 11

excess a-chains, bind to membrane and produce damage , toxic at high concs. –> hemolysis

Allelic heterogeneity- 150 different mutations

32
Q

β-thalassemia Treatment

A

bone marrow

transplantation from an HLA-identical sibling

33
Q

Hemophilia A & B

A

X-linked recessive bleeding disorders

deficiency in Factor 8 (Hem A) and Factor 9 (Hem B)

hemorrhage into joints and muscles

easy bruising and prolonged bleedings

34
Q

Genetics of Hemophilia A & B

A

Genes for both Factors on long arm of X-chromosome

Factor 8 (large): 40% large inversion disrupting gene or 60% deletions/insertions/point mutation

Factor 9 (small): point mutations and deletions in gene

35
Q

Inheritance Pattern for Hemophilia

A

Affected male → carrier female → Affected male

Carrier mother, 50% change passing faulty X to daughter

Affected father will always pass affected gene to daughters (obligate carriers)

36
Q

Phenotypes of carrier females

A

generally asymptomatic b/c of random X inactivation/ Lyonization - normal hemostasis

Manifesting heterozygote: lower level of clotting
factors b/c of skewed X
inactivation

37
Q

Recombinant protein

A

manufacture of clotting factors replaces pooled serum